Australia markets closed

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
30.85+0.41 (+1.35%)
At close: 04:00PM EDT
30.85 0.00 (0.00%)
After hours: 07:56PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close30.44
Open30.50
Bid0.00 x 1000
Ask0.00 x 1400
Day's range29.90 - 31.07
52-week range15.72 - 146.16
Volume557,644
Avg. volume1,682,551
Market cap1.236B
Beta (5Y monthly)0.94
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target estN/A
  • GlobeNewswire

    Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program

    - $209.7 Million Cash and Cash Equivalents at March 31, 2022 – - Over 120 Patients Now Enrolled in Phase 3 Program - AUSTIN, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the first quarter ended March 31, 2022 and provided a clinical update on its Phase 3 clinical program of simufilam in Alzheimer’s disease. Simufilam is Cassava Sciences’ lead drug candida

  • GlobeNewswire

    Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference

    - Q&A Session at Conference on Wednesday, April 27th at 1:30PM Eastern - AUSTIN, Texas, April 25, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has been invited to participate in the B. Riley Securities’ Neuroscience Conference, a virtual event taking place on April 27-28, 2022. Remi Barbier, President & CEO, will participate in a Q&A session hosted by B. Riley Securities’ equity rese

  • GlobeNewswire

    Webcast Details for Cassava Sciences’ Upcoming Fireside Chat

    – All Stakeholder Are Welcome to Listen by Webcast – – Event To Be Held Tuesday, April 5th, 9am ET – AUSTIN, Texas, April 04, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced webcast details for an upcoming, previously announced presentation and fireside chat with Remi Barbier, President & CEO and Eric Schoen, Chief Financial Officer. This event is scheduled to take place on Tuesday, April 5th a